Best Infectious Diseases Companies in China
The 86 best Infectious Diseases companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
Tracking the best Infectious Diseases companies in China by disclosed equity funding puts $3.8 billion on the table across 86 tracked companies, and the concentration at the top is striking. Abogen Biosciences alone accounts for $1.1 billion of that, making every other player look like a rounding error by comparison. Clover Biopharma follows at $400 million, Ascletis at $255 million, and then the numbers drop fast. One unicorn in the cohort. Hillhouse, Qiming Venture Partners, and Legend Capital are the names showing up most often on cap tables, which tells you something about where conviction is sitting right now.
So what's actually moving the needle this quarter? Coverage is flat in the traditional sense, but the hot themes are anything but quiet. Vaccine candidates, tuberculosis reactivation, and neglected tropical diseases are drawing real attention, partly because global disease burden arguments keep putting pressure on capital allocators to look beyond the obvious. And as recent thinking on infectious disease innovation makes clear, the pipeline logic has shifted toward underfunded pathogen categories. I'd watch that tuberculosis reactivation angle closely, especially as China's regulatory environment pushes developers toward differentiated programs. The directory you're browsing reflects that tension between concentrated mega-rounds and a long tail of smaller bets still finding their footing.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in China
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 49 mo ago | Series C | Dr InBev Co-Founder & Co-CEO | — | Animate.cssjQueryHSTS | 157 patents mRNA and circular RNA therapeutics with lipid nanoparticle delivery systems | — |
| 2 | Clover Biopharma Developer of drugs to treat autoimmune, cancer and infectious diseases 67Funding top 13%Market top 25%Global top 44%Moat top 48% All 6 signals ▾Fundingtop 13% Markettop 25% Globaltop 44% Moattop 48% Newsbottom 32% Techbottom 24% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Market: 681 employees (top 2% of Life Sciences) · Serving 4 countries incl. United States, China, United Kingdom rank vs industry peers · Fliar Intelligence Index 67/100 | $400M | 2 mo ago | Public | — | 681 | — | — | — |
| 3 | Hualan Bioengineering Chinese vaccine and blood products manufacturer | $293M | 69 mo ago | Public | Jingsong Wang Founder & CEO | 3,243 | — | — | — |
| 4 | Ascletis Developer of small molecules for the treatment of multiple diseases 42Funding top 19%Product top 30%Moat top 31%Innovation top 34% All 10 signals ▾Fundingtop 19% Producttop 30% Moattop 31% Innovationtop 34% Talentbottom 49% Marketbottom 42% Growthbottom 42% Globalbottom 36% Techbottom 30% Newsbottom 24% Funding: Raised $255M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) Product: 6 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 42/100 | $255M | 3 mo ago | Series B | Jinzi Wu Founder & CEO | 41 | PHPJW PlayerBootstrap+6 | — | — |
| 5 | Beijing Mabworks Biotech Developer of anticancer therapies | $214M | 74 mo ago | Series C | — | 285 | — | — | — |
| 6 | Souzhou Ribo Life Science Developer of nucleic acid drugs based on RNA interference (RNAi) technology | $201M | 46 mo ago | Public | Zicai Liang Founder | 228 | — | — | — |
| 7 | RecBio Developer of vaccines to prevent infectious disease | $172M | 66 mo ago | Public | Yong Liu Founder & CEO | — | BootstrapjQuerySwiper+4 | — | — |
| 8 | CanSino Biologics Developer of vaccines for the treatment of infectious diseases | $107M | 31 mo ago | Public | Helen Mao Co-Founder | 2,291 | Animate.cssNginxSwiper+1 | 115 patents Adenoviral vector vaccines and inhalable nucleic‑acid lipid nanoparticle delivery systems | — |
| 9 | Beijing Huanuotai Biomedical Technology Developer of vaccines for the treatment of infectious diseases | $104M | 26 mo ago | Series B | Wang Hailong CEO | — | — | — | — |
| 10 | Argo Biopharma Developer of oligonucleotide therapeutics for various diseases | $104M | 31 mo ago | Series A | Shiwei Xia Co-Founder | — | — | — | — |
| 11 | Evopoint Developer of therapeutics for multiple diseases | $97M | 28 mo ago | Series E | Nianfeng Ju Co-Founder | — | — | — | — |
| 12 | MAXVAX Biotechnology Developer of vaccines for infectious diseases 57Funding top 22%Market top 40%Moat top 42%Talent bottom 49% All 5 signals ▾Fundingtop 22% Markettop 40% Moattop 42% Talentbottom 49% Globalbottom 36% Funding: Raised $84.8M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) Market: 100 employees (top 20% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 57/100 | $85M | 6 mo ago | Series D | Dexiang Chen Founder | 100 | — | — | — |
| 13 | Drug Farm Developer of a novel treatment for metabolic diseases | $83M | 37 mo ago | Series C | Tong Li Co-Founder & CSO | 118 | — | — | — |
| 14 | Luzhu Biotech Developer of human vaccines and biological drugs for multiple diseases | $73M | 47 mo ago | Public | Jian Kong CEO | 129 | — | — | — |
| 15 | Walvax Chinese vaccine manufacturer specializing in vaccines for meningitis and influenza | $73M | 142 mo ago | Public | — | 2,249 | PHPTailwind CSSscrollreveal+5 | — | — |
| 16 | Ustar Biotechnologies Isothermal amplification kits for pathogen detection and genotyping of infectious diseases | $62M | 54 mo ago | Series E | — | 65 | WordPressMySQLPHP+21 | 31 patents Integrated microfluidic nucleic acid detection platforms for rapid CRISPR‑based diagnostics | — |
| 17 | Thermona Developer of RNA technology-based drugs to address various diseases | $60M | 48 mo ago | Series A | Wei Wensheng Founder | — | — | — | — |
| 18 | Zhimeng Biopharma Developer of drugs for the treatment of chronic hepatitis B (CHB) and related liver diseases | $49M | 67 mo ago | Series A | Zhijun Zhang Co-Founder | — | — | 127 patents Small-molecule potassium channel modulators for epilepsy and neuroprotection | — |
| 19 | Frontier Biotechnologies Clinical stage pharmaceutical company developing AIDS treatment drug | $43M | 113 mo ago | Series C | — | 392 | — | 31 patents RNAi therapeutics targeting specific disease-related genes for medical treatment | — |
| 20 | Junshi BioPharma Provider of antibody-based therapeutics for multiple diseases | $31M | 99 mo ago | Public | — | 2,772 | — | — | — |
| 21 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 8 mo ago | Series B | Rongkuan Hu Founder | — | — | — | — |
| 22 | Chengdu Wiskin Biomedical Technology Developer of drugs for the treatment of EBV-related tumors | $21M | 42 mo ago | Series A | Yuquan Wei Co-Founder | — | — | — | — |
| 23 | Changchun Zhuoyi Biological Developer of rabies vaccine | $21M | 72 mo ago | Late Stage | Feng Xingfu CEO | 465 | — | — | — |
| 24 | Third Wave Technologies Molecular diagnostic test devices and reagents | $19M | 222 mo ago | Acquired | Kevin Conroy CEO | 179 | TurbopackNode.jsPHP+18 | — | — |
| 25 | Xintong Medicine Developer of drugs for treating multiple diseases | $15M | 69 mo ago | Series C | — | 92 | — | — | — |
| 26 | Healrna Developer of nucleic acid drugs to treat various diseases | $15M | 39 mo ago | Seed | Zhong Tianyi Co-Founder & CEO | — | — | — | — |
| 27 | Kemi Biopharmaceutical Developer of immunotherapeutics for oncology and infectious disease | $14M | 44 mo ago | Series A | Shi Yuenian Founder | — | — | — | — |
| 28 | YolTech Developer of gene editing and LNP delivery platforms for therapeutics 27Funding top 37%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 37% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $14.1M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 27/100 | $14M | 9 mo ago | Series B | Yuxuan Wu Founder & CEO | — | — | — | — |
| 29 | Bendao Gene Technology Provider of a gene-editing platform for the treatment of genetic diseases | $11M | 62 mo ago | Series A | Cai Yujia Founder | — | PHPparticles.jsLayui+5 | — | — |
Top 12 Infectious Diseases companies in China
#1
Public · Chengdu, Sichuan Sheng · founded 2007 · 681 employees$400Mraised▾
Developer of drugs to treat autoimmune, cancer, and infectious diseases. The company has developed its proprietary Trimer-Tag technology to develop novel, trimerized fusion-protein therapies. The trimerized fusion proteins have been shown to have a much better binding and therapeutic response. The company's drug pipeline include SCB-808, in a ready-for-injection prefilled syringe formulation and SCB-313 for Oncology.
- Mar 2026Post IPO$3.6M
- Apr 2024Post IPO$320.7K
- May 2023Post IPO$48.9M
- Dec 2022Post IPO$64.4M
#2
Series B · Hangzhou, Zhejiang · founded 2011 · 41 employees$255Mraised▾
Developer of small molecules for the treatment of multiple diseases. It offers pipeline of drug candidates which include Ritonavir for Covid, Ravidasvir for HCV, ASC22 for HIV, ASC40 for NASH, acne, solid tumor, breast cancer, and others.
- Feb 2026Post IPO$107.9M
- Jan 2017Series B$100M
- Dec 2015Series B$20M
- Sep 2015Series B$35M
#3
Series D · Lanzhou, Gansu · founded 2016 · 100 employees$84.8Mraised▾
Developer of vaccines for infectious diseases. It offers an adjuvant platform, recombinant protein expression platform, and mRNA platform for developing preventive and therapeutic vaccines for influenza vaccine, rabies vaccine, rotavirus vaccine, and herpes zoster vaccine.
- Dec 2025Series D—
- Jul 2024Series C$41.3M
- Feb 2024Series C$41.9M
- Jul 2022Series B—
#4
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
#5
Series B · Shanghai, Shanghai · founded 2021$14.1Mraised▾
Developer of gene editing and LNP delivery platforms for therapeutics. It focuses on creating novel tools for genome editing using metagenomics data. It develops in vivo gene-editing medicines for genetic, metabolic, cancer, and cardiovascular diseases. It is researching treatments for diseases such as familial hypercholesterolemia and hereditary transthyretin amyloidosis.
- Sep 2025Series B$45M
- Nov 2023Series A$14.1M
- Feb 2022Angel—
- Series A—
#6
Series C · Suzhou, Jiangsu · founded 2019$1.1Braised▾
Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.
- May 2022Series C—
- Nov 2021Series C$300M
- Aug 2021Series C$720M
- Apr 2021Series B$91.6M
#7
Series B · Beijing, Beijing · founded 2019$104.4Mraised▾
Developer of vaccines for the treatment of infectious diseases. The company specializes in the development and industrialization of human vaccine products and innovative adjuvants for COVID-19, influenza, malaria and herpes zoster.
- Mar 2024Series B$84M
- Mar 2021Series A$20.4M
#8
Series E · Suzhou, Jiangsu · founded 2017$97.3Mraised▾
Developer of therapeutics for multiple diseases. It offers a drug pipeline that includes BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and antibody-drug conjugates for the treatment of cancer, infectious disease, and metabolic disease.
- Feb 2024Series E$97.3M
#9
Public · Tianjin, Tianjin · founded 2009 · 2291 employees$107.4Mraised▾
Developer of vaccines for the treatment of infectious diseases. It is specialized in developing and manufacturing a series of vaccine products, including pneumonia protein vaccines, pertussis vaccines, and recombined tuberculosis vaccines.
- Oct 2023Post IPO$2M
- Apr 2017Series C$65.4M
- Oct 2015Series B$30M
- Sep 2013Series A$10M
#10
Series A · Shanghai, Shanghai · founded 2021$103.8Mraised▾
Developer of oligonucleotide therapeutics for various diseases. The company specializes in siRNA drug discovery and development, utilizing siRNA platform technology and RADS to offer a pipeline of therapeutics for cardiovascular, rare diseases, CNS diseases, viral hepatitis, metabolic diseases, and more.
- Nov 2023Series A$41M
- Mar 2022Seed$62.8M
#11
Public · Suzhou, Jiangsu · founded 2007 · 228 employees$200.8Mraised▾
Developer of nucleic acid drugs based on RNA interference (RNAi) technology. The company focuses on RNAi technology, drug discovery, siRNA design and screening, chemical modification, delivery technology, PD/PK study, safety evaluation, clinical trial, and other related aspects. Also, offers siRNA therapeutics against Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, HIV, etc.
- Jul 2022Series E$40M
- Apr 2020Series C$66.2M
- Dec 2019Series C$28.8M
- Mar 2017Series B$39.1M
#12
Series C · Shanghai, Shanghai · founded 2015 · 118 employees$83Mraised▾
Drug Farm is a developer of a novel treatment for metabolic diseases. The company uses AI-directed medicinal chemistry to develop small molecule drugs against new targets. The product pipeline includes DF-006 for hepatitis-B, DF-007 for fatty liver disease, DF-008 for Cancer, and DF-003 for rare blindness.
- May 2023Series C$27M
- Feb 2021Series A$56M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in China
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 3,336 China-affiliated papers.
- Chinese Academy of Medical Sciences & Peking Union Medical College188
- Peking University172
- Chinese Academy of Sciences160
- Shanghai Jiao Tong University159
- Fudan University140
- Liquid biopsy20→216
- Point-of-care testing24→173
- Point of care14→100
- Cancer12→84
- Detection limit8→71
- Liquid biopsy62→410
- Cancer30→159
- Biomarker14→138
- Biopsy11→129
- Point-of-care testing53→138
- Liquid biopsy17→119
- Cancer9→51
- Biopsy9→42
- Biomarker4→37
- Precision medicine2→33
Where diagnostics is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in China
China diagnostics patent filing is accelerating — 33 filings from 15 assignees (2016–2025), led by Autobio Labtec Instr, Chengdu Illumaxbio TECH, UNIV CITY HONG KONG; annual filings 1→6.
- Autobio Labtec Instr6
- Chengdu Illumaxbio TECH6
- UNIV CITY HONG KONG4
- Phase Scient International4
- Ankon Medical TECH Shanghai3
- Shenzhen Mindray Animal Medical 3
- UNIV Fuzhou1
- Pharus Taiwan1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.